Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 4Active not recruiting 3Completed 2Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Carboplatin 126Cisplatin 125Drug Therapy 104Bevacizumab 98Oxaliplatin 97Capecitabine 96Radiotherapy 94Gemcitabine 87Paclitaxel 85tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 63Injections 62Fluorouracil 62sintilimab 57anlotinib 53Surgical Procedures, Operative 50130-nm albumin-bound paclitaxel 50Docetaxel 49fludarabine 46Pemetrexed 45Standard of Care 43venetoclax 42Leucovorin 42Biopsy 42Irinotecan 41lenvatinib 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Medrol Veriderm × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡